The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma | Radiation Oncology | Full Text
Understanding Survival Analyses | SpringerLink
Overall survival in days from initial diagnosis | Download Scientific Diagram
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab | Anticancer Research
Chapter 20 Survival Analysis | Econometrics for Business Analytics
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma | Haematologica
Oncotarget | Clofarabine/busulfan-based reduced intensity conditioning regimens... | Oncotarget
Overall survival from date of LMD relapse. Median survival 39 days (95%... | Download Scientific Diagram
Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Survival Analysis in R
27 Survival analysis | The Epidemiologist R Handbook
Real-World Progression-Free Survival as an Endpoint in Advanced Non-Small-Cell Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Data Derived From Electronic Health Records | medRxiv
Survival Analysis in R
Overall survival curve for the “all taxa” data set (Kaplan-Meier estimate and corresponding 95% confidence intervals; N = 4447; the length of time axis is limited to a maximum of 15 days).
Kaplan-Meier estimates of cumulative overall survival a | Open-i
The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma | Journal of Neuro-Oncology
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text
Cancers | Free Full-Text | Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study
Long-term survival and quality of life after intensive care for patients 80 years of age or older | Annals of Intensive Care | Full Text
223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice | European Journal of Nuclear Medicine and Molecular Imaging
Entropy | Free Full-Text | Focused Information Criterion for Restricted Mean Survival Times: Non-Parametric or Parametric Estimators
